Cargando…

Quantitative determination of niraparib and olaparib tumor distribution by mass spectrometry imaging

Rationale: Optimal intratumor distribution of an anticancer drug is fundamental to reach an active concentration in neoplastic cells, ensuring the therapeutic effect. Determination of drug concentration in tumor homogenates by LC-MS/MS gives important information about this issue but the spatial inf...

Descripción completa

Detalles Bibliográficos
Autores principales: Morosi, Lavinia, Matteo, Cristina, Ceruti, Tommaso, Giordano, Silvia, Ponzo, Marianna, Frapolli, Roberta, Zucchetti, Massimo, Davoli, Enrico, D'Incalci, Maurizio, Ubezio, Paolo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7085221/
https://www.ncbi.nlm.nih.gov/pubmed/32210725
http://dx.doi.org/10.7150/ijbs.41395
_version_ 1783508902197854208
author Morosi, Lavinia
Matteo, Cristina
Ceruti, Tommaso
Giordano, Silvia
Ponzo, Marianna
Frapolli, Roberta
Zucchetti, Massimo
Davoli, Enrico
D'Incalci, Maurizio
Ubezio, Paolo
author_facet Morosi, Lavinia
Matteo, Cristina
Ceruti, Tommaso
Giordano, Silvia
Ponzo, Marianna
Frapolli, Roberta
Zucchetti, Massimo
Davoli, Enrico
D'Incalci, Maurizio
Ubezio, Paolo
author_sort Morosi, Lavinia
collection PubMed
description Rationale: Optimal intratumor distribution of an anticancer drug is fundamental to reach an active concentration in neoplastic cells, ensuring the therapeutic effect. Determination of drug concentration in tumor homogenates by LC-MS/MS gives important information about this issue but the spatial information gets lost. Targeted mass spectrometry imaging (MSI) has great potential to visualize drug distribution in the different areas of tumor sections, with good spatial resolution and superior specificity. MSI is rapidly evolving as a quantitative technique to measure the absolute drug concentration in each single pixel. Methods: Different inorganic nanoparticles were tested as matrices to visualize the PARP inhibitors (PARPi) niraparib and olaparib. Normalization by deuterated internal standard and a custom preprocessing pipeline were applied to achieve a reliable single pixel quantification of the two drugs in human ovarian tumors from treated mice. Results: A quantitative method to visualize niraparib and olaparib in tumor tissue of treated mice was set up and validated regarding precision, accuracy, linearity, repeatability and limit of detection. The different tumor penetration of the two drugs was visualized by MSI and confirmed by LC-MS/MS, indicating the homogeneous distribution and higher tumor exposure reached by niraparib compared to olaparib. On the other hand, niraparib distribution was heterogeneous in an ovarian tumor model overexpressing the multidrug resistance protein P-gp, a possible cause of resistance to PARPi. Conclusions: The current work highlights for the first time quantitative distribution of PAPRi in tumor tissue. The different tumor distribution of niraparib and olaparib could have important clinical implications. These data confirm the validity of MSI for spatial quantitative measurement of drug distribution providing fundamental information for pharmacokinetic studies, drug discovery and the study of resistance mechanisms.
format Online
Article
Text
id pubmed-7085221
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Ivyspring International Publisher
record_format MEDLINE/PubMed
spelling pubmed-70852212020-03-24 Quantitative determination of niraparib and olaparib tumor distribution by mass spectrometry imaging Morosi, Lavinia Matteo, Cristina Ceruti, Tommaso Giordano, Silvia Ponzo, Marianna Frapolli, Roberta Zucchetti, Massimo Davoli, Enrico D'Incalci, Maurizio Ubezio, Paolo Int J Biol Sci Research Paper Rationale: Optimal intratumor distribution of an anticancer drug is fundamental to reach an active concentration in neoplastic cells, ensuring the therapeutic effect. Determination of drug concentration in tumor homogenates by LC-MS/MS gives important information about this issue but the spatial information gets lost. Targeted mass spectrometry imaging (MSI) has great potential to visualize drug distribution in the different areas of tumor sections, with good spatial resolution and superior specificity. MSI is rapidly evolving as a quantitative technique to measure the absolute drug concentration in each single pixel. Methods: Different inorganic nanoparticles were tested as matrices to visualize the PARP inhibitors (PARPi) niraparib and olaparib. Normalization by deuterated internal standard and a custom preprocessing pipeline were applied to achieve a reliable single pixel quantification of the two drugs in human ovarian tumors from treated mice. Results: A quantitative method to visualize niraparib and olaparib in tumor tissue of treated mice was set up and validated regarding precision, accuracy, linearity, repeatability and limit of detection. The different tumor penetration of the two drugs was visualized by MSI and confirmed by LC-MS/MS, indicating the homogeneous distribution and higher tumor exposure reached by niraparib compared to olaparib. On the other hand, niraparib distribution was heterogeneous in an ovarian tumor model overexpressing the multidrug resistance protein P-gp, a possible cause of resistance to PARPi. Conclusions: The current work highlights for the first time quantitative distribution of PAPRi in tumor tissue. The different tumor distribution of niraparib and olaparib could have important clinical implications. These data confirm the validity of MSI for spatial quantitative measurement of drug distribution providing fundamental information for pharmacokinetic studies, drug discovery and the study of resistance mechanisms. Ivyspring International Publisher 2020-02-21 /pmc/articles/PMC7085221/ /pubmed/32210725 http://dx.doi.org/10.7150/ijbs.41395 Text en © The author(s) This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
spellingShingle Research Paper
Morosi, Lavinia
Matteo, Cristina
Ceruti, Tommaso
Giordano, Silvia
Ponzo, Marianna
Frapolli, Roberta
Zucchetti, Massimo
Davoli, Enrico
D'Incalci, Maurizio
Ubezio, Paolo
Quantitative determination of niraparib and olaparib tumor distribution by mass spectrometry imaging
title Quantitative determination of niraparib and olaparib tumor distribution by mass spectrometry imaging
title_full Quantitative determination of niraparib and olaparib tumor distribution by mass spectrometry imaging
title_fullStr Quantitative determination of niraparib and olaparib tumor distribution by mass spectrometry imaging
title_full_unstemmed Quantitative determination of niraparib and olaparib tumor distribution by mass spectrometry imaging
title_short Quantitative determination of niraparib and olaparib tumor distribution by mass spectrometry imaging
title_sort quantitative determination of niraparib and olaparib tumor distribution by mass spectrometry imaging
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7085221/
https://www.ncbi.nlm.nih.gov/pubmed/32210725
http://dx.doi.org/10.7150/ijbs.41395
work_keys_str_mv AT morosilavinia quantitativedeterminationofniraparibandolaparibtumordistributionbymassspectrometryimaging
AT matteocristina quantitativedeterminationofniraparibandolaparibtumordistributionbymassspectrometryimaging
AT cerutitommaso quantitativedeterminationofniraparibandolaparibtumordistributionbymassspectrometryimaging
AT giordanosilvia quantitativedeterminationofniraparibandolaparibtumordistributionbymassspectrometryimaging
AT ponzomarianna quantitativedeterminationofniraparibandolaparibtumordistributionbymassspectrometryimaging
AT frapolliroberta quantitativedeterminationofniraparibandolaparibtumordistributionbymassspectrometryimaging
AT zucchettimassimo quantitativedeterminationofniraparibandolaparibtumordistributionbymassspectrometryimaging
AT davolienrico quantitativedeterminationofniraparibandolaparibtumordistributionbymassspectrometryimaging
AT dincalcimaurizio quantitativedeterminationofniraparibandolaparibtumordistributionbymassspectrometryimaging
AT ubeziopaolo quantitativedeterminationofniraparibandolaparibtumordistributionbymassspectrometryimaging